<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03670316</url>
  </required_header>
  <id_info>
    <org_study_id>300000632</org_study_id>
    <nct_id>NCT03670316</nct_id>
  </id_info>
  <brief_title>Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care</brief_title>
  <official_title>Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy of an algorithm designed to recommend smoking cessation-related
      pharmacotherapy options to the primary care providers of smokers living with HIV/AIDS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Smoking remains the leading cause of preventable death and disability in the United States.
      Whereas smoking has declined significantly among individuals in the general population, it is
      clustered in populations of vulnerable individuals such as people living with HIV/AIDS (PLWH)
      in whom smoking prevalence rates and resulting comorbidity rates remain high. Medical
      advances in the treatment of HIV have resulted in substantial increases in life expectancy
      among PLWH and as a consequence PLWH smokers are now, more than ever, at heightened risk for
      tobacco-related illnesses and death. PLWH smokers engaged in treatment lose more years of
      life due to smoking now than to HIV disease. Although PLWH smokers engaged in HIV care
      typically see a medical provider every 4-6 months, smoking cessation treatment and referral
      is often not part of routine HIV care. While 94% of HIV treatment providers indicated that
      they would be willing to provide smoking cessation services to their patients, few have
      received training in how to provide smoking cessation services. With seven first line
      pharmacotherapies available for smoking cessation, development of algorithms to assist
      providers in selecting the most appropriate pharmacotherapy is an important but untested
      strategy to increase smoking cessation in PLWH. The purpose of this proposal is to conduct a
      mixed efficacy/effectiveness trial comparing an algorithm treatment with prescription cost
      off sets and quit line referral (AT) to an enhanced Treatment as Usual (quit line referral
      only; eTAU) group. Six hundred PLWH smokers will be recruited at the University of Alabama at
      Birmingham, University of Washington, and Fenway Health HIV clinics and will be randomized to
      receive AT or eTAU. All AT smokers will receive active treatment for twelve weeks regardless
      of stated motivation or intention to quit. eTAU smokers will be referred to quit line
      services and HIV providers may elect to treat smoking as part of standard of care.
      Participants will remain in the study for 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized to either the Algorithm Treatment plus referral to a quitline (AT) or the quitline alone condition (eTAU).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>7-day point-prevalence abstinence</measure>
    <time_frame>6 months</time_frame>
    <description>Number of cigarettes smoked over the past 7 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cigarettes per day</measure>
    <time_frame>6 months</time_frame>
    <description>Number of cigarettes reported being smoked per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour quit attempts</measure>
    <time_frame>6 months</time_frame>
    <description>Attempt to not smoke for 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of prescriptions written</measure>
    <time_frame>6 months</time_frame>
    <description>The number of prescriptions written for a participant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>HIV</condition>
  <condition>AIDS</condition>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Algorithm Treatment plus referral to quitline (AT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will be assigned a pharmacotherapy treatment regimen recommended to their provider.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quitline (eTAU)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will be referred to quitlines, telephone-based tobacco cessation services.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Algorithm Treatment</intervention_name>
    <description>Varenicline was selected as the first line of treatment for patients willing to take a medication twice per day and wanting cessation. Following varenicline, bupropion and then NRT are subsequent options. In terms of preference for NRT, nicotine patches would be the first option followed by lozenge, gum, inhaler, and nasal spray. The order of NRT within the algorithm is based upon patient familiarity and number of clinical trials supporting their use. Combination NRT (e.g., patch and lozenge) or adding NRT to varenicline or bupropion is offered to participants who have made an unsuccessful quit attempt with these medications in the past. If none of these medications are appropriate, then the participant is offered counseling only.</description>
    <arm_group_label>Algorithm Treatment plus referral to quitline (AT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quitline only</intervention_name>
    <description>eTAU participants will complete the same algorithm questions but will not have this information sent to their provider, although their provider may elect to prescribe medication as part of standard of care. Participants will be referred to a quitline for behavioral support services for cessation.</description>
    <arm_group_label>Quitline (eTAU)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Enrollment in the CNICS clinical cohort.

          2. 18 years or older;

          3. Receiving HIV care at the UAB, UW or Fenway Health clinics and not anticipating
             changing clinics over the next six months

          4. Smoking greater than or equal to 5 cigarettes per day (cpd) for the past month

          5. Living in an unrestricted environment that allows smoking.

        Exclusion Criteria:

          1. Cognitive impairment such that unable to provide informed consent;

          2. Non-English speaking;

          3. Acutely suicidal, manic, acutely intoxicated, or otherwise not stable enough to
             provide informed consent;

          4. Currently receiving smoking cessation treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karen L Cropsey, Psy.D.</last_name>
    <phone>2059757809</phone>
    <email>kcropsey@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keith Chichester, B.A.</last_name>
    <phone>2059757809</phone>
    <email>krc80@uab.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Keith Chichester, B.A.</last_name>
      <phone>205-975-7809</phone>
      <email>krc80@uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Sisson, M.A.</last_name>
      <phone>205-975-7809</phone>
      <email>msisson2@uab.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Karen Cropsey, Psy.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Seger, J. C., Horn, D. B., Westman, E. C., Lindquist, R., Scinta, W., Richardson, L. A., ... &amp; Bays, H. E. (2013). American Society of Bariatric Physicians Obesity Algorithm: Adult Adiposity Evaluation and Treatment 2013.</citation>
  </reference>
  <reference>
    <citation>Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Gali√® N. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S78-84. doi: 10.1016/j.jacc.2009.04.017. Review.</citation>
    <PMID>19555861</PMID>
  </reference>
  <reference>
    <citation>Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009 Jan;32(1):193-203. doi: 10.2337/dc08-9025. Epub 2008 Oct 22.</citation>
    <PMID>18945920</PMID>
  </reference>
  <reference>
    <citation>Hughes JR. An updated algorithm for choosing among smoking cessation treatments. J Subst Abuse Treat. 2013 Aug;45(2):215-21. doi: 10.1016/j.jsat.2013.01.011. Epub 2013 Mar 19.</citation>
    <PMID>23518288</PMID>
  </reference>
  <reference>
    <citation>Hughes J. An algorithm for choosing among smoking cessation treatments. J Subst Abuse Treat. 2008 Jun;34(4):426-32. Epub 2007 Sep 14.</citation>
    <PMID>17869475</PMID>
  </reference>
  <reference>
    <citation>Bader P, McDonald P, Selby P. An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts. Tob Control. 2009 Feb;18(1):34-42. doi: 10.1136/tc.2008.025635. Epub 2008 Oct 9.</citation>
    <PMID>18845621</PMID>
  </reference>
  <reference>
    <citation>Kunyk D, Els C, Papadakis S, Selby P. Tobacco use disorder treatment in primary care: implementing a clinical system pathway in Alberta. Can Fam Physician. 2014 Jul;60(7):646-55.</citation>
    <PMID>25022640</PMID>
  </reference>
  <reference>
    <citation>Fiore, M. C., C. R. Jaen, et al. (2008). Treating tobacco use and dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD, US Public Health Service.</citation>
  </reference>
  <reference>
    <citation>Shuter J, Bernstein SL, Moadel AB. Cigarette smoking behaviors and beliefs in persons living with HIV/AIDS. Am J Health Behav. 2012 Jan;36(1):75-85.</citation>
    <PMID>22251785</PMID>
  </reference>
  <reference>
    <citation>Schnoll RA, Rukstalis M, Wileyto EP, Shields AE. Smoking cessation treatment by primary care physicians: An update and call for training. Am J Prev Med. 2006 Sep;31(3):233-9. Epub 2006 Jul 24.</citation>
    <PMID>16905034</PMID>
  </reference>
  <reference>
    <citation>Aveyard P, Begh R, Parsons A, West R. Brief opportunistic smoking cessation interventions: a systematic review and meta-analysis to compare advice to quit and offer of assistance. Addiction. 2012 Jun;107(6):1066-73. doi: 10.1111/j.1360-0443.2011.03770.x. Epub 2012 Feb 28. Review.</citation>
    <PMID>22175545</PMID>
  </reference>
  <reference>
    <citation>Carpenter MJ, Hughes JR, Gray KM, Wahlquist AE, Saladin ME, Alberg AJ. Nicotine therapy sampling to induce quit attempts among smokers unmotivated to quit: a randomized clinical trial. Arch Intern Med. 2011 Nov 28;171(21):1901-7. doi: 10.1001/archinternmed.2011.492.</citation>
    <PMID>22123796</PMID>
  </reference>
  <reference>
    <citation>Ingersoll KS, Cropsey KL, Heckman CJ. A test of motivational plus nicotine replacement interventions for HIV positive smokers. AIDS Behav. 2009 Jun;13(3):545-54. Epub 2007 Dec 8.</citation>
    <PMID>18066659</PMID>
  </reference>
  <reference>
    <citation>Lloyd-Richardson EE, Stanton CA, Papandonatos GD, Shadel WG, Stein M, Tashima K, Flanigan T, Morrow K, Neighbors C, Niaura R. Motivation and patch treatment for HIV+ smokers: a randomized controlled trial. Addiction. 2009 Nov;104(11):1891-900. doi: 10.1111/j.1360-0443.2009.02623.x. Epub 2009 Aug 28.</citation>
    <PMID>19719796</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Karen Cropsey</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

